(MENAFN- GlobeNewsWire - Nasdaq) U.S. Gastroparesis Drug Market is projected to grow from USD 1.68 Billion in 2025 to USD 2.60 Billion by 2035 due to rising diabetes influence across the countryAustin, April 08, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Gastroparesis Drug Market size is valued at USD 5.11 Billion in 2025 and is projected to reach USD 8.22 Billion by 2035, growing at a CAGR of 4.90% during 2025–2035.
Due to the rising prevalence of diabetes, gastrointestinal illnesses, unresolved medical problems, and medication advances, the expansion of the gastroparesis drug market is fueled by improvements in therapies for disorders with delayed gastric emptying.
Get a Sample Report of Gastroparesis Drug Market Growth Strategy @
Gastroparesis Drug Market Size and Forecast:
Market Size in 2025: USD 5.11 Billion Market Size by 2035: USD 8.22 Billion CAGR: 4.90% from 2026 to 2035 Base Year: 2025 Forecast Period: 2026–2035 Historical Data: 2022–2024
The U.S. Gastroparesis Drug Market is projected to grow from USD 1.68 Billion in 2025 to USD 2.60 Billion by 2035, at a CAGR of 4.46%.
Growth is fueled by rising gastroparesis diagnoses, rising diabetes prevalence, expanding access to gastroenterology care, and continued use of cutting-edge pharmaceutical treatments for symptom relief.
Rising Diabetes Prevalence and Delayed Gastric Emptying Cases Propel Market Expansion Globally
One of the key elements that significantly affects the gastroparesis drug market is the rising prevalence of diabetes mellitus and gastrointestinal motility problems. The industry is anticipated to benefit from early treatment and symptom management brought about by an increase in diagnosis and patient education. Additionally, the market will advance due to rising demand for medications used to treat symptoms including nausea and vomiting.
Gastroparesis Drug Market Segmentation Analysis:
By Drug Class
Prokinetic Agents held the largest market share of 34.78% in 2025 owing to high usage of prokinetics agents in clinical practice for enhancing gastric motility and symptom control including delayed gastric emptying, nausea and bloating. Ghrelin Agonists are expected to grow at the fastest CAGR of 6.43% during 2026–2035 due to its novel mechanism of stimulating appetite and gastric motility.
By Disease Type
Diabetic Gastroparesis dominated with a 52.16% market share in 2025 as diabetes stands to be key reasons of delayed gastric emptying and large expanding patient pool with requiring pharmacological treatment. Idiopathic Gastroparesis is projected to register the fastest CAGR of 5.27% through 2026–2035 driven by increasing diagnosis rates and provider awareness.
By Route of Administration
Oral held the largest share of 61.89% in 2025 owing to its convenience, non-invasive characteristic and high patient compliance. Injectable is anticipated to grow at the fastest CAGR of 5.91% during the forecast period primarily used in patients with severe or refractory cases, where rapid symptom relief is needed.
By Distribution Channel
Hospital Pharmacies accounted for the highest market share of 46.32% in 2025 due to hospitals being at the center for dispensing prescribed or dispensed medications. Online Pharmacies are expected to expand at the fastest CAGR of 6.08% through 2026–2035 with the digital healthcare adoption and home delivery services.
For a Custom Market Outlook Discussion with Our Analysts, Connect Now @
Gastroparesis Drug Market Regional Insights:
North America Gastroparesis Drug Market has a major presence in the industry, capturing 38.62% of the market share in 2025. This is attributed to the high prevalence rate of diabetes in the region, along with the established healthcare system.
The fastest-growing market is the Asia-Pacific Gastroparesis Drug Market, which is expected to increase at a CAGR of 6.43% between 2025 and 2035. Growing diabetes cases, digestive issues, and health consciousness in nations like China, India, Japan, and Southeast Asia will propel this market.
Major Players Analysis Listed in the Gastroparesis Drug Market Report:
Evoke Pharma Vanda Pharmaceuticals Neurogastrx Processa Pharmaceuticals CinDome Pharma Renexxion Ireland Dr. Falk Pharma GmbH AbbVie AstraZeneca GlaxoSmithKline (GSK) Abbott Laboratories Bausch Health Theravance Biopharma Zydus Group ANI Pharmaceuticals Takeda Pharmaceutical Johnson & Johnson Pfizer Teva Pharmaceutical Sun Pharmaceuticals Industries
Gastroparesis Drug Market Recent Developments:
In August 2025, Evoke Pharma continued advancing and commercializing GIMOTI, strengthening its gastroparesis portfolio through extended patent protection, improved physician adoption, and sustained focus on diabetic gastroparesis symptom management, supporting long-term market exclusivity and treatment accessibility. In June 2025, Vanda Pharmaceuticals progressed its tradipitant program for gastroparesis through ongoing regulatory discussions and clinical evaluations, reinforcing its commitment to receptor-targeted therapies while expanding its gastrointestinal pipeline and pursuing potential approvals to strengthen its market position.
Purchase Comprehensive Gastroparesis Drug Market Report – Single User PDF @
Exclusive Sections of the Report (The USPs):
EPIDEMIOLOGY & PATIENT DEMAND ANALYTICS – helps you understand disease prevalence, incidence growth linked to diabetes and obesity, diagnosis gaps, and treatment-seeking behavior across patient segments. CLINICAL OUTCOMES & TREATMENT EFFICACY METRICS – helps you evaluate symptom relief rates, gastric emptying improvement, hospitalization reduction, and relapse rates across available therapies. DRUG SAFETY & LONG-TERM TOLERABILITY INSIGHTS – helps you assess adverse event incidence and risk factors associated with prolonged use of gastroparesis medications. PIPELINE & INNOVATION TRACKER – helps you identify ongoing clinical trials, novel mechanism-based therapies, regulatory approvals, and advancements in personalized treatment approaches. R&D INVESTMENT & REGULATORY LANDSCAPE ANALYSIS – helps you uncover pharmaceutical investment trends, orphan drug designations, and evolving approval dynamics in key markets. MARKET COMPETITION & COMMERCIAL STRATEGY INSIGHTS – helps you analyze market share distribution, pricing trends, therapy adoption (mono vs. combination), geographic expansion, and strategic partnerships among key players.
Gastroparesis Drug Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 5.11 Billion |
| Market Size by 2035 | USD 8.22 Billion |
| CAGR | CAGR of 4.90% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Key Segments | . By Drug Class (Prokinetic Agents, Antiemetic Drugs, Motilin Receptor Agonists, Dopamine Receptor Antagonists, Serotonin (5-HT4) Receptor Agonists, Ghrelin Agonists, Others)
. By Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, Others)
. By Route of Administration (Oral, Injectable, Others)
. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Data
Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Comments
No comment